NO20026171L - Topiske farmasöytiske formuleringer og fremgangsmåter for behandling - Google Patents

Topiske farmasöytiske formuleringer og fremgangsmåter for behandling

Info

Publication number
NO20026171L
NO20026171L NO20026171A NO20026171A NO20026171L NO 20026171 L NO20026171 L NO 20026171L NO 20026171 A NO20026171 A NO 20026171A NO 20026171 A NO20026171 A NO 20026171A NO 20026171 L NO20026171 L NO 20026171L
Authority
NO
Norway
Prior art keywords
formulation
agent
treatment
methods
pharmaceutical formulations
Prior art date
Application number
NO20026171A
Other languages
English (en)
Other versions
NO20026171D0 (no
NO333292B1 (no
Inventor
John Nicholas Staniforth
Michael John Tobyn
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of NO20026171D0 publication Critical patent/NO20026171D0/no
Publication of NO20026171L publication Critical patent/NO20026171L/no
Publication of NO333292B1 publication Critical patent/NO333292B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Det beskrives en farmasøytisk formulering for topisk tilførsel til et pattedyr, der denne formulering består av en enhetsdose med en terapeutisk effektiv mengde av et terapeutisk. middel og et farmasøytisk akseptabelt bærermedium for dette middel. Nevnte formulering er ved omgivelsestemperatur i fast form og har et bløtgjøringspunkt som ikke er over 35°C, slik at når formuleringen blir plassert i kontinuerlig kontakt med huden til en pattedyrspasient blir den bløtgjort og oppnår en konsistens som bevirker betydelig tilførsel av enhetsdosen av. nevnte terapeutiske middel på et ønsket hudområde hos pattedyrspasienten innen en tidsperiode på mindre enn 10 minutter.
NO20026171A 2000-06-26 2002-12-20 Topiske farmasoytiske formuleringer samt anvendelse av et terapeutisk middel for fremstilling av slike NO333292B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015617.4A GB0015617D0 (en) 2000-06-26 2000-06-26 Improved preparations for dermal delivery of active substances
PCT/GB2001/002823 WO2002000203A1 (en) 2000-06-26 2001-06-26 Topical pharmaceutical formulations and methods of treatment

Publications (3)

Publication Number Publication Date
NO20026171D0 NO20026171D0 (no) 2002-12-20
NO20026171L true NO20026171L (no) 2003-02-10
NO333292B1 NO333292B1 (no) 2013-04-29

Family

ID=9894412

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026171A NO333292B1 (no) 2000-06-26 2002-12-20 Topiske farmasoytiske formuleringer samt anvendelse av et terapeutisk middel for fremstilling av slike

Country Status (21)

Country Link
US (3) US7754240B2 (no)
EP (2) EP2027851A1 (no)
JP (1) JP2004501185A (no)
KR (1) KR20030041871A (no)
CN (1) CN1438878A (no)
AT (1) ATE429904T1 (no)
AU (2) AU2001267686A1 (no)
BR (1) BR0112356A (no)
CA (1) CA2413699C (no)
DE (1) DE60138547D1 (no)
DK (1) DK1296652T3 (no)
ES (1) ES2325980T3 (no)
GB (1) GB0015617D0 (no)
HK (1) HK1056311A1 (no)
HU (1) HUP0301121A3 (no)
IL (1) IL153665A0 (no)
MX (1) MXPA02012666A (no)
NO (1) NO333292B1 (no)
PL (1) PL211890B1 (no)
WO (1) WO2002000203A1 (no)
ZA (1) ZA200210224B (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
GB2383950B (en) * 2002-01-11 2006-01-18 Cosmetic Warriors Ltd Cosmetic product
AU2003223005A1 (en) * 2002-05-06 2003-11-17 Vectura Limited Application device for topical administration of pharmaceutical agents
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
DE102004059613A1 (de) * 2004-12-10 2006-06-14 Liedtke, Rainer K., Dr. Zusammensetzung und Methode einer topischen Therapie von Neurodermitis
GB0524959D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Topical compositions for treatment of respiratory disorders
GB0524961D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents for systemic effect
WO2007066147A1 (en) * 2005-12-07 2007-06-14 Pharmakodex Ltd Topical compositions for paediatric use
BRPI0709674A2 (pt) 2006-03-31 2011-12-06 Stiefel Res Australia Pty Ltd gel de suspensão espumante
GB0612556D0 (en) * 2006-06-23 2006-08-02 Univ Aston Topical pharmaceutical formulations
US20090221703A1 (en) * 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
CA2655809C (en) * 2006-07-21 2013-10-01 Bridge Pharma, Inc. Dermal anesthetic compounds
US20080287373A1 (en) * 2007-05-17 2008-11-20 Popp Karl F Topical skin treating kits
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
BRPI0910382B1 (pt) 2008-07-18 2021-07-06 Biomod Concepts Inc Artigo para aplicar um ingrediente ativo, veículo de aplicação para transferência de micropartículas a um substrato, micropartícula para liberar um ingrediente ativo e método para liberar um ingrediente ativo
CA2738524C (en) 2008-10-02 2013-11-26 Mylan Inc. Method for making a multilayer adhesive laminate
US10543166B2 (en) * 2009-06-26 2020-01-28 Taris Biomedical Llc Implantable drug delivery devices and methods of making the same
US8470304B2 (en) 2009-08-04 2013-06-25 Avidas Pharmaceuticals Llc Therapeutic vitamin D sun-protecting formulations and methods for their use
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
WO2012010238A1 (en) 2010-07-17 2012-01-26 Merck Patent Gmbh Enhancement of penetration and action
EP2543364A1 (en) * 2010-10-14 2013-01-09 Deva Holding Anonim Sirketi Formulations of cetyl myristate and/or cetyl palmitate
WO2012051374A2 (en) 2010-10-15 2012-04-19 The Procter & Gamble Company Use of monoamine oxidase inhibitors to improve epithelial biology
US8293288B2 (en) 2011-02-23 2012-10-23 Edna Ma Pain relieving composition
US8512768B2 (en) 2011-02-23 2013-08-20 Miss Smarty Pants Enterprises, Inc. Pain relieving composition
US9925264B2 (en) 2011-05-10 2018-03-27 Itochu Chemical Frontier Corporation Non-aqueous patch
US11786455B2 (en) 2011-05-10 2023-10-17 Itochu Chemical Frontier Corporation Non-aqueous patch
BR112013028802B1 (pt) 2011-05-10 2021-10-26 Itochu Chemical Frontier Corporation Curativo adesivo não-aquoso
WO2013046335A1 (ja) 2011-09-27 2013-04-04 伊藤忠ケミカルフロンティア株式会社 非水性貼付剤
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN102641275B (zh) * 2012-05-16 2013-04-24 江苏圣宝罗药业有限公司 复方丙酸氯倍他索与维a酸软膏剂
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
CA2903020C (en) 2013-02-28 2019-06-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid formulations and its compostions
EP2968880A1 (en) 2013-03-15 2016-01-20 TARIS Biomedical LLC Drug delivery devices with drug-permeable component and methods
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
KR102488491B1 (ko) 2013-08-19 2023-01-12 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6793715B2 (ja) 2015-03-23 2020-12-02 バイオファーミクス・インコーポレイテッドＢｉｏＰｈａｒｍＸ， Ｉｎｃ． テトラサイクリンの皮膚用医薬組成物
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
CN108853140A (zh) * 2018-07-18 2018-11-23 豆立忠 一种多药物模块软膏及其制备方法
KR20210042412A (ko) 2018-09-06 2021-04-19 주식회사 이노파마스크린 천식 또는 파킨슨병 치료를 위한 방법 및 조성물
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN112237547B (zh) * 2020-09-28 2022-08-30 安徽美邸康药业有限公司 一种药贴成型装置
MX2020011523A (es) * 2020-10-29 2022-05-02 Exeltis Pharma Mexico S A De C V Composicion farmaceutica adecuada para administracion vaginal en forma de ovulos y uso de la misma.
BE1028968B1 (nl) 2020-12-29 2022-08-01 Usocore Nv Harde was zonder BHT
WO2024064151A1 (en) * 2022-09-21 2024-03-28 The Board Of Trustees Of The Leland Stanford Junior University Synergistic stimulation of mucociliary clearance to treat mucus obstruction in cystic fibrosis and other muco-obstructive disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US597849A (en) * 1898-01-25 Ditching-jack
US369784A (en) * 1887-09-13 fueman
US308343A (en) * 1884-11-25 Pail handle
US151274A (en) * 1874-05-26 Improvement in springs for vehicles
US765986A (en) * 1902-06-07 1904-07-26 Nat Tube Co Conical rolls for piercing, expanding, or cross-rolling metal billets or tubular blanks.
US863941A (en) * 1906-06-05 1907-08-20 James M Robbins Wheelwright-machine.
US892890A (en) * 1907-10-14 1908-07-07 Max A Repelow Card-index.
AU513753B2 (en) * 1974-07-08 1980-12-18 Johnson & Johnson Antimicrobial composition
DE2551446B2 (de) * 1975-11-15 1977-09-15 Karl Werner Schlüter GmbH, 2000 Ham burg Verfahren zur herstellung von suppositorien
CH637014A5 (de) * 1978-09-29 1983-07-15 Sandoz Ag Verfahren zur herstellung von suppositorien.
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
US4278679A (en) * 1980-05-01 1981-07-14 Chromalloy American Corporation Combination of two or more drugs in a single dosage form wherein one of the drugs is a physostigmine compound
FR2515036B1 (fr) * 1981-10-23 1986-12-05 Oreal Composition stable a l'oxydation d'anthraline ou de l'un de ses derives et son utilisation dans le traitement des maladies de la peau
CH655004A5 (fr) 1981-10-23 1986-03-27 Oreal Composition anhydre, stable a l'oxydation, d'un compose d'anthraline dans un alkyl-ester d'acide gras en vue du traitement des maladies de la peau.
US4892890A (en) * 1984-11-01 1990-01-09 G. D. Searle And Company External analgesic compositions
DE3522060A1 (de) * 1985-06-20 1987-01-08 Liedtke Pharmed Gmbh Arzneipflaster fuer systemische anwendungen
DE3523454A1 (de) * 1985-07-01 1987-01-08 Eberhard Prof Dr Nuernberg Formkoerper
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
FR2633187A1 (fr) 1988-06-23 1989-12-29 Gafner Paul Felix Dispositif applicateur cutane d'une solution medicamenteuse pour le traitement dermatologique
AU622961B2 (en) * 1988-12-23 1992-04-30 Westech Industrial Ltd. Flame arrester having detonation-attenuating means
LU87416A1 (fr) * 1988-12-29 1990-07-10 Cird Microgranules charges en une substance active,constitues essentiellement d'un triglyceride d'acides gras satures et leur utilisation par voie topique dans le domaine therapeutique
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
FR2663007A1 (fr) 1990-06-08 1991-12-13 Kodak Pathe Emballage de produits photographiques en bandes.
US5121158A (en) * 1990-10-31 1992-06-09 Umax Data System Inc. Filter driving mechanism for color optical reader
JP3086290B2 (ja) * 1991-07-26 2000-09-11 エスエス製薬株式会社 ジクロフェナクナトリウム貼付剤
JPH07258071A (ja) * 1994-03-22 1995-10-09 Ojiro Yukagaku Kenkyusho:Kk 粒状皮膚用剤およびその用途
US5597849A (en) * 1994-11-14 1997-01-28 Medical Polymer Technologies, Inc. Stick formulations for topical drug delivery of therapeutic agents and uses thereof
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
DE19524691A1 (de) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
US5722424A (en) * 1995-09-29 1998-03-03 Target Therapeutics, Inc. Multi-coating stainless steel guidewire
JPH09169635A (ja) * 1995-12-20 1997-06-30 Sekisui Chem Co Ltd 経皮吸収製剤
GB9611356D0 (en) * 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
ES2179646T3 (es) * 1998-04-27 2003-01-16 Surmodics Inc Revestimiento que libera un agente bioactivo.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6325807B1 (en) * 1999-06-11 2001-12-04 Scimed Life Systems, Inc. Variable strength sheath
US6455066B1 (en) * 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6517520B2 (en) * 2000-12-21 2003-02-11 Ethicon Endo Surgery, Inc. Peripherally inserted catheter with flushable guide-tube

Also Published As

Publication number Publication date
AU2006202479C1 (en) 2010-06-10
AU2006202479A1 (en) 2006-07-06
DK1296652T3 (da) 2009-08-17
CA2413699C (en) 2010-10-12
EP1296652A1 (en) 2003-04-02
NO20026171D0 (no) 2002-12-20
ZA200210224B (en) 2003-06-18
EP1296652B1 (en) 2009-04-29
JP2004501185A (ja) 2004-01-15
US7754240B2 (en) 2010-07-13
ATE429904T1 (de) 2009-05-15
NO333292B1 (no) 2013-04-29
PL211890B1 (pl) 2012-07-31
HUP0301121A3 (en) 2006-07-28
HK1056311A1 (en) 2004-02-13
US20080166413A1 (en) 2008-07-10
US8158613B2 (en) 2012-04-17
ES2325980T3 (es) 2009-09-28
BR0112356A (pt) 2003-05-06
US20030138503A1 (en) 2003-07-24
US20100273760A1 (en) 2010-10-28
IL153665A0 (en) 2003-07-06
KR20030041871A (ko) 2003-05-27
DE60138547D1 (de) 2009-06-10
AU2001267686A1 (en) 2002-01-08
MXPA02012666A (es) 2004-07-30
AU2006202479B2 (en) 2009-08-20
WO2002000203A1 (en) 2002-01-03
EP2027851A1 (en) 2009-02-25
CN1438878A (zh) 2003-08-27
GB0015617D0 (en) 2000-08-16
PL360868A1 (en) 2004-09-20
HUP0301121A2 (hu) 2003-09-29
CA2413699A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
NO20026171L (no) Topiske farmasöytiske formuleringer og fremgangsmåter for behandling
NO20061859L (no) OROS Push Stick for kontrollert tilforsel av aktive midler
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
ES2082288T3 (es) Composiciones terapeuticas para administracion intranasal de ketorolaco.
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
PL334348A1 (en) Method of treating prostate diseases using vitamin d formulations of retarded and/or prolonged release
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
AR037592A1 (es) Formulaciones farmaceuticas de 5,7,14-triazatetraciclo (10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
WO2007022090A3 (en) Topical delivery with a carrier fluid
DE60121303D1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
HUP0401867A2 (hu) A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére
Martini et al. Efficacy and Tolerability of Fitostimoline in Two Different Forms (Soaked Gauzes and Cream) and Citrizan Gel in the Topical Treatment of Second‐Degree Superficial Cutaneous Burns
NO20062234L (no) Transdemisk,farmasoytisk spray-formulering omfattende en VP/UA kopolymer og en ikke-vandig vehikkel
SG146638A1 (en) Pharmaceutical delivery system
DK1343472T3 (da) Thixotropisk næsespray
JP2002530353A5 (no)
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
NZ703464A (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease
Dhaon et al. Efficacy and Safety of Nimesulide Transdermal Gel versus Diclofenac and Piroxicarn Gel in Patients with Acute Musculoskeletal Condition
HUP0104619A2 (hu) PDE inhibitorok alkalmazása húgyhólyagbetegségek kezelésére szolgáló gyógyszerkészítmény előállítására
WO2023150579A3 (en) Pharmaceutical formulations containing nalbuphine

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees